Drug-class evidence
Dulaglutide clinical trials
2 pivotal trials of dulaglutide, spanning Trulicity. 10,478 total participants across the published evidence base.
What we know about dulaglutide
Dulaglutide is a once-weekly GLP-1 receptor agonist marketed as Trulicity for type 2 diabetes. The AWARD program established glycemic efficacy across multiple comparator backgrounds, and the REWIND trial demonstrated a 12% reduction in major adverse cardiovascular events over a median 5.4 years in a primarily primary-prevention diabetes population.
Effect sizes across dulaglutide trials
All dulaglutide trials
Trials cited are for the FDA-approved branded products containing dulaglutide. Compounded versions have not been studied in equivalent randomized controlled trials. GLP1Zoom does not provide medical advice; discuss treatment with your prescribing clinician. Full disclaimer.
References(4)
Our sourcing standards →- REWIND (NCT01394952) — registry record — ClinicalTrials.gov (NIH)
- REWIND — primary publicationPubMed — The Lancet 2019
- AWARD-7 (NCT01621178) — registry record — ClinicalTrials.gov (NIH)
- AWARD-7 — primary publicationPubMed — The Lancet Diabetes & Endocrinology 2018